Unknown Manufacturer
Epcoritamab is a bispecific CD20-directed CD3 T-cell engager used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults.
Epcoritamab is a bispecific CD20-directed CD3 T-cell engager used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults.
Epcoritamab is a humanized bispecific IgG1 antibody that targets CD20 on B-cells and CD3 on T-cells. Unlike other monoclonal antibodies that target a single receptor on the surface of lymphocytes, epcoritamab can recognize and bind two different targets, the CD3 receptor expressed on the surface of T-cells and CD20 expressed on the surface of lymphoma cells and healthy B-lineage cells. By targeting both receptors, epcoritamab promotes the release of proinflammatory cytokines and the lysis of CD20+ malignant B-cells through selective T-cell–mediated cytotoxic activity.
Epcoritamab is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
2 associated conditions
